The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Differential genomic landscape of estrogen receptor (ER)-low versus ER-positive (ER+) and ER-negative (ER-) metastatic breast cancer (MBC).
 
Chiara Corti
Research Funding - Lilly (Inst)
Travel, Accommodations, Expenses - Veracyte
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Sreekar Challa
No Relationships to Disclose
 
Ningxuan Zhou
No Relationships to Disclose
 
Alyssa Martin
No Relationships to Disclose
 
Yvonne Li
No Relationships to Disclose
 
Melissa Hughes
No Relationships to Disclose
 
Andrew Cherniack
Consulting or Advisory Role - KaryoVerse
Research Funding - Bayer
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Elizabeth Mittendorf
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Alight Sciences; AstraZeneca; AstraZeneca; BioNTech SE; Merck; Merck; Moderna Therapeutics
Research Funding - Gilead Sciences (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharpe and Dohme
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb; Roche/Genentech
 
Nancy Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Artera; AstraZeneca; Blueprint Medicines; Daiichi Sankyo; Eisai; Johnson & Johnson/Janssen; Menarini; Olema Pharmaceuticals; Pfizer; Seagen
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
Travel, Accommodations, Expenses - AstraZeneca; Olema Pharmaceuticals
 
Nabihah Tayob
No Relationships to Disclose
 
Sara Tolaney
Consulting or Advisory Role - AADi; Ambrx; Artios Biopharmaceuticals; Arvinas; AstraZeneca; Bayer; BeiGene; Bicycle Therapeutics; BioNTech; Blueprint Medicines; Bristol-Myers Squibb; Circle Pharma; Cullinan Oncology; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Jazz Pharmaceuticals; Johnson & Johnson; Launch Therapeutics; Lilly; Menarini Group; Merck; Mersana; Natera; Novartis; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Summit Therapeutics; Systimmune; Tango Therapeutics; Zentalis; Zuellig Pharma; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo; Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Menarini/Stemlin (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Arvinas; Gilead Sciences; Jazz Pharmaceuticals; Lilly; Pfizer; Sanofi
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Gilead Sciences
 
Ana Garrido-Castro
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer
Research Funding - 4D Path (Inst); AstraZeneca (Inst); Biovica (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Precede Bio (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Merck; Novartis; Pfizer; Roche/Genentech